Stryker Corporation $SYK Shares Sold by EULAV Asset Management

Key Points

• EULAV Asset Management cut its Stryker stake by 55.6% in the third quarter, selling 23,000 shares and retaining 18,371 shares valued at approximately $5.1 million. Institutional investors collectively own 77.09% of the company.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and a $369 target price, despite several firms recently lowering their price targets.
• Insider selling was significant: company insiders sold 351,267 shares worth about $118.2 million over the past three months, including a $100.8 million sale by director Ronda Stryker.

EULAV Asset Management trimmed its holdings in Stryker Corporation (NYSE:SYK - Free Report) by 55.6% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 18,371 shares of the medical technology company's stock after selling 23,000 shares during the period. EULAV Asset Management's holdings in Stryker were worth $5,059,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Mitchell Mcleod Pugh & Williams Inc. grew its position in shares of Stryker by 1.2% during the first quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 2,678 shares of the medical technology company's stock worth $880,000 after buying an additional 31 shares in the last quarter. Community Bank & Trust Waco Texas boosted its stake in Stryker by 2.3% during the 2nd quarter. Community Bank & Trust Waco Texas now owns 1,395 shares of the medical technology company's stock valued at $439,000 after acquiring an additional 31 shares during the last quarter. Cornerstone Financial Management LLC boosted its stake in Stryker by 66.0% during the 2nd quarter. Cornerstone Financial Management LLC now owns 78 shares of the medical technology company's stock valued at $25,000 after acquiring an additional 31 shares during the last quarter. NWF Advisory Services Inc. boosted its stake in Stryker by 2.3% during the 2nd quarter. NWF Advisory Services Inc. now owns 1,472 shares of the medical technology company's stock valued at $463,000 after acquiring an additional 33 shares during the last quarter. Finally, Harold Davidson & Associates Inc. grew its holdings in Stryker by 0.4% during the 1st quarter. Harold Davidson & Associates Inc. now owns 8,668 shares of the medical technology company's stock worth $2,848,000 after acquiring an additional 34 shares in the last quarter. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on SYK shares. Truist Financial dropped their target price on shares of Stryker from $340.00 to $310.00 and set a "hold" rating for the company in a research report on Tuesday, October 6th. Raymond James Financial set a $370.00 target price on shares of Stryker in a research note on Friday, July 31st. Citigroup reduced their price target on shares of Stryker from $399.00 to $360.00 and set a "buy" rating on the stock in a research report on Thursday, September 10th. BTIG Research decreased their price target on Stryker from $358.00 to $316.00 and set a "buy" rating for the company in a research note on Monday, October 12th. Finally, Royal Bank Of Canada lowered their price objective on Stryker from $435.00 to $420.00 and set an "outperform" rating for the company in a report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $369.00.

Insider Activity

In other news, Director Ronda Stryker sold 300,000 shares of Stryker stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total value of $100,770,000.00. Following the completion of the transaction, the director directly owned 2,301,375 shares of the company's stock, valued at approximately $773,031,862.50. The trade was a 11.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Dylan Crotty sold 441 shares of the business's stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $328.61, for a total transaction of $144,917.01. Following the sale, the insider directly owned 6,102 shares of the company's stock, valued at approximately $2,005,178.22. This represents a 6.74% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 351,267 shares of company stock valued at $118,197,701. Company insiders own 4.60% of the company's stock.

Stryker Stock Performance

SYK stock opened at $307.65 on Monday. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. The firm has a market cap of $118.01 billion, a P/E ratio of 31.88, a P/E/G ratio of 1.98 and a beta of 0.78. Stryker Corporation has a 12-month low of $267.00 and a 12-month high of $389.33. The stock's 50 day simple moving average is $295.23 and its 200 day simple moving average is $311.79.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping analysts' consensus estimates of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. During the same quarter in the previous year, the company posted $3.13 earnings per share. The firm's revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, equities research analysts predict that Stryker Corporation will post 14.93 EPS for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date is Wednesday, September 30th. Stryker's dividend payout ratio (DPR) is presently 36.48%.

About Stryker

Stryker Corporation NYSE: SYK is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company's product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.